

Prof Brian Kirby
Professor Brian Kirby is Consultant Dermatologist at St Vincent’s University Hospital, Dublin, Ireland, and Full Clinical Professor at University College Dublin, Ireland.
Professor Kirby’s clinical and research interests include psoriasis and hidradenitis suppurativa. He is co-Chair of the Dublin Hidradenitis Suppurativa Research Group and a Principal Investigator at the Charles Institute of Dermatology at University College Dublin.
Professor Kirby is also a former member of the steering committee of British Association of Dermatologists Biologics and Immunomodulatory Register (BADBIR), a member of the International Psoriasis Council (IPC), a member of the scientific committee of the European Hidradenitis Suppurativa Foundation (EHSF) and Chairperson of the Clinical Advisory Group of Dermatology at the Royal College of Physicians of Ireland.
He has authored or co-authored more than 250 publications, the majority of which are on psoriasis and hidradenitis suppurativa. Additionally, he is Associate Editor of the British Journal of Dermatology and Dermatology.
Achieving MDA or DAPSA treatment targets improves quality of life for patients with PsA.1–4 Explore the characteristics of patients who report treatment success...
ASDAS and BASDAI are commonly used in clinical practice.1,2 However, discover recent studies demonstrating that a high proportion of real-world patients do not...
Explore which treatment targets may be more appropriate for making treatment decisions in axSpA.
PsA and axSpA have overlapping disease manifestations which are driven by inflammation.1 Explore several extracellular cytokines that are implicated in these...
Watch Prof Frank Behrens discuss the importance of treating skin symptoms in addition to musculoskeletal symptoms for patients with SpA.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...